Brief: Bioventus Agrees To Nationwide Contract With Cigna Commercial Plans For Durolane And Gelsyn-3
02/05/2022 12:34
May 2 (Reuters) - Bioventus Inc BVS.O :
* BIOVENTUS AGREES TO NATIONWIDE CONTRACT WITH CIGNA
COMMERCIAL
PLANS FOR DUROLANE® AND GELSYN-3® FOR KNEE OSTEOARTHRITIS
* BIOVENTUS INC - DUROLANE WILL BE EXCLUSIVE TO ALL CIGNA
PATIENTS
WHILE GELSYN-3 WILL BE ONE OF TWO MULTI-INJECTION HA PRODUCTS
UNDER CONTRACT
Source text for Eikon: ID:nGNX6Q0C0z
Further company coverage: BVS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Bioventus
See all newsBioventus Q1 revenue rises 7%, beats expectations
U.S. STOCKS ON THE MOVE -Erasca Inc, Regenxbio, Natgas stocks
U.S. STOCKS ON THE MOVE-American Eagle Outfitters, gold miners, EPAM
U.S. STOCKS ON THE MOVE -Burlington Stores, Berkshire Hathaway, Bioventus
Bioventus rises after better-than-expected quarterly results